New combo therapy shows promise in early cancer trial

NCT ID NCT04354246

First seen May 14, 2026 · Last updated May 14, 2026

Summary

This early-stage study tested a new drug called COM902, alone or with another drug (COM701), in 94 people with advanced cancers like ovarian, lung, colon, and multiple myeloma. The main goal was to check safety and find the best dose. While not a cure, the approach aims to control tumor growth in patients who have run out of standard options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Florida Cancer Specialists

    Sarasota, Florida, 34230, United States

  • Froedtert & Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • MD Anderson Cancer Center.

    Houston, Texas, 77030, United States

  • Mary Crowley Cancer Research

    Dallas, Texas, 75230, United States

  • Massachusetts General Hospital.

    Boston, Massachusetts, 02114, United States

  • START Midwest.

    Grand Rapids, Michigan, 49503, United States

  • The Ohio State University Comprehensive Cancer Center.

    Columbus, Ohio, 43210, United States

  • The START Center for Cancer Care.

    San Antonio, Texas, 78229, United States

  • The University of Tennessee WEST Cancer Center.

    Memphis, Tennessee, 38138, United States

Conditions

Explore the condition pages connected to this study.